Safety and efficacy of anagrelide in Japanese post-marketing surveillance, with subgroup analyses on the effect of previous cytoreductive therapies, age, and starting dose

BACKGROUND: In Japan, anagrelide has been approved for use in patients with essential thrombocythemia. Here, the safety and efficacy of anagrelide was assessed in clinical practice as post-marketing surveillance. Subgroup analyses were conducted to compare patients (1) with or without a history of c...

Descripción completa

Detalles Bibliográficos
Autores principales: Komatsu, Norio, Hashimoto, Yoshinori, Baba, Terumi, Otsuka, Manami, Akimoto, Takafumi, Fernandez, Jovelle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Nature Singapore 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9515010/
https://www.ncbi.nlm.nih.gov/pubmed/35624199
http://dx.doi.org/10.1007/s12185-022-03380-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9515010/
https://www.ncbi.nlm.nih.gov/pubmed/35624199
http://dx.doi.org/10.1007/s12185-022-03380-2

Ejemplares similares